Is Mirvetuximab Soravtansine Better Than Chemotherapy in FRα-Expressing Recurrent Ovarian Cancer?

In November 2023, the FDA granted accelerated approval to mirvetuximab soravtansine-gynx (MIRV), an antibody–drug conjugate that targets folate receptor alpha (FRα), based on the positive results of the single-arm SORAYA trial of MIRV in Fra-high, platinum-resistant ovarian cancer (J Clin Oncol 2023; 41:2436).

Now, investigators report the industry-sponsored, global, open-label phase 3 MIRASOL study, in which 453 patients were randomized to either investigator's choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) or MIRV (6 mg/kg every 3 weeks). Eligible patients had platinum-resistant disease, had received 1 to 3 lines of prior systemic therapy, and had high FRα tumor expression by immunohistochemical staining…